Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC and Pembrolizumab in Advanced Melanoma Progressed on Anti-PD1/L1 Therapy
NCT02965716Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jun 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 5 years. Started Jun 2018; status: active, not recruiting.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02965716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965716.